Can Spravato Help With Suicidal Thoughts? What Patients Should Know

For patients experiencing severe depression, one of the most urgent concerns is the presence of suicidal thoughts.

Spravato is one of the few treatments specifically studied and approved for major depressive disorder with acute suicidal ideation or behavior. That makes it an important option in situations where faster symptom relief is needed.

Understanding how Spravato fits into this context — and what it can and cannot do — is critical.

Spravato (esketamine) is FDA-approved for:

• Treatment-resistant depression
• Major depressive disorder with acute suicidal ideation or behavior

This second indication is what makes Spravato distinct from most traditional antidepressants, which can take weeks to begin working.

Spravato works on glutamate pathways in the brain, which are different from the serotonin pathways targeted by most antidepressants.

Because of this, some patients experience:

• Faster reduction in depressive symptoms
• Decreased intensity of suicidal thoughts
• Improved emotional responsiveness

For patients in acute distress, the speed of response can be clinically meaningful.

Spravato is not a standalone emergency intervention.

It is always used:

• Alongside an oral antidepressant
• Within a structured treatment plan
• Under medical supervision in a certified clinic

Patients experiencing active suicidal crisis may still require:

• Immediate psychiatric evaluation
• Crisis stabilization
• Additional levels of care

Spravato is part of a broader treatment strategy — not a replacement for emergency services.

When used for patients with suicidal ideation, Spravato treatment includes:

• Careful screening and evaluation
• Close monitoring during each session
• Ongoing psychiatric oversight
• Coordination with other mental health providers when needed

Safety and structure are especially important in these situations.

Spravato may be considered when:

• Depression is severe and persistent
• Suicidal thoughts are present
• Traditional medications have not provided sufficient relief

Eligibility is determined through a clinical evaluation that considers safety, history, and current symptoms.

Because of its effects — including dissociation and blood pressure changes — Spravato must be administered in a controlled setting.

This ensures:

• Patients are monitored throughout treatment
• Side effects are managed appropriately
• Care decisions are made in real time

This level of oversight is especially important for patients in vulnerable states.

Spravato is not a quick fix, but it represents an important advancement in how severe depression and suicidal thinking can be treated.

For some patients, it provides a path forward when other treatments have not worked.

For others, it becomes one part of a larger, coordinated care plan.

If you or someone you know is experiencing suicidal thoughts, immediate support is critical.

In the U.S., you can call or text 988 to reach the Suicide & Crisis Lifeline.

If you are considering Spravato as part of a longer-term treatment plan, a clinical evaluation can help determine whether it is appropriate and how it would fit into your care.

You can learn more about Spravato treatment at Therapeutic Infusions on our Spravato treatment page.